Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioVie, Inc. filings document a Nevada clinical-stage biopharmaceutical company with Nasdaq-listed Class A common stock and, in certain filings, warrants tied to its capital structure. Material-event reports cover securities offerings, underwriting agreements and issuances involving units, pre-funded units and warrants.
Proxy statements and related 8-K filings describe annual meeting voting matters, director elections, board appointments and amendments to the company’s omnibus equity incentive plan. Registration statement amendments provide formal disclosure for offering activity and financial-statement periods associated with BioVie’s development-stage operations.
BioVie Inc.'s President and CEO, Cuong Do, has filed a Schedule 13D reporting beneficial ownership of 399,018 shares of the company’s Class A common stock, representing 5.03% of the class. The filing aggregates shares, warrants and stock options held directly and through Do & Rickles Investments, LLC.
The percentage is based on 7,541,539 shares outstanding as of March 23, 2026, plus 388,119 shares issuable upon exercise of warrants and options exercisable within 60 days. The securities were acquired with personal funds and as equity compensation and are described as a long-term investment, though the reporting persons may buy or sell in the future.
BioVie Inc. is a clinical-stage biotech reporting a net loss of about $6.1M for the quarter and $11.2M for the six months ended December 31, 2025, both slightly improved versus the prior year as research and administrative costs declined.
The company ended the period with cash and cash equivalents of $20.5M, working capital of roughly $18.8M, and stockholders’ equity of about $19.3M, but its accumulated deficit reached approximately $363.3M. Management states there is substantial doubt about its ability to continue as a going concern without additional financing.
BioVie is advancing bezisterim (NE3107) for Parkinson’s disease, long COVID and Alzheimer’s disease, and BIV201 for cirrhosis and ascites. A Phase 2b Parkinson’s study completed enrollment of 60 patients with topline data expected in the first half of 2026, and a DOD-funded long COVID Phase 2 trial is underway. The Alzheimer’s Phase 3 trial was left underpowered after excluding patients from sites with protocol and cGCP issues. The company also formed Option Therapeutics for a potential spin-off of its liver program and filed an S-1 for a possible IPO.
BioVie Inc. reported that Chief Medical Officer Joseph M. Palumbo received a grant of 132,000 stock options on January 5, 2026.
The options, held directly, have an exercise price of $1.31 per share, were granted at no cost, and are exercisable for 132,000 shares of common stock. According to the vesting schedule, 55% of the options vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. Any unexercised options expire on January 5, 2036.
BioVie Inc. reported that its Chief Financial Officer, Joanne Wendy Kim, received a grant of stock options on January 5, 2026. The award covers 110,100 stock options with an exercise price of $1.31 per share, giving her the right to buy BioVie common stock at that price in the future. The filing shows she directly holds all 110,100 options after this transaction.
According to the vesting schedule, 55% of the options vested on January 5, 2026, meaning more than half became exercisable immediately. The remaining options are set to vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029, aligning her long-term incentives with the company’s performance over several years.
BioVie Inc. director Sigmund Rogich reported new option grants. On January 5, 2026, he was awarded stock options covering 70,000 shares and an additional 141,100 shares of BioVie common stock, each with an exercise price of $1.31 per share.
The 70,000-share option grant vests in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. For the 141,100-share grant, 75% vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.
BioVie Inc. reported an insider equity award connected to its President & CEO, Cuong V Do. On January 5, 2026, Do & Rickles Investments LLC, an entity associated with him, was granted a stock option to buy 665,300 shares of BioVie common stock at an exercise price of $1.31 per share. The option was reported as an indirect holding.
According to the vesting terms, 55% of the options vested on January 5, 2026, with the remaining balance vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. The filing shows a grant price of $0 for the derivative security itself, which reflects that this was an option award rather than an open‑market purchase.
BioVie Inc. director Michael Edward Sherman received new stock option awards. On January 5, 2026, he was granted stock options to purchase 80,000 shares of BioVie common stock at an exercise price of $1.31 per share, expiring on January 5, 2031. These options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the company’s 2026 annual shareholders’ meeting.
On the same date, he was also granted stock options to purchase 341,100 shares of common stock at the same $1.31 exercise price, also expiring on January 5, 2031. For this grant, 75% of the options vested on January 5, 2026, with the remaining 25% vesting in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Both grants are reported as directly owned.
BioVie Inc. director Kameel D. Farag received a grant of 57,500 stock options on January 5, 2026. The options have an exercise price of $1.31 per share and, if not exercised, expire on January 5, 2031. Each option is exercisable for one share of BioVie common stock, giving Farag the right to buy up to 57,500 shares.
According to the vesting terms, 7,500 options vest on the grant date, while the remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. After this grant, Farag beneficially holds 57,500 derivative securities in the form of these stock options.
BioVie Inc. director Amy Suzon Chappell reported receiving a stock option grant on January 5, 2026. The award covers options to purchase 57,500 shares of BioVie common stock at an exercise price of $1.31 per share, with no cash paid for the grant itself.
According to the vesting terms, 7,500 shares underlying the options vest on the grant date. The remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and on the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. The options expire on January 5, 2031 if not exercised.